- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Marlborough Today
By the People, for the People
Banque Pictet & Cie SA Reduces Boston Scientific Stake
Swiss bank lowers position in medical device company by 13.3% in Q4 2025
Apr. 2, 2026 at 7:34am
Got story updates? Submit your updates here. ›
Banque Pictet & Cie SA, a Swiss private bank, lowered its position in Boston Scientific Corporation (NYSE:BSX) by 13.3% in the fourth quarter of 2025, according to a recent SEC filing. The bank now owns 270,871 shares of the medical equipment provider's stock, valued at $25.83 million.
Why it matters
This filing provides insight into the investment strategies of major institutional investors like Banque Pictet & Cie SA, which can signal broader trends in the medical device industry and investor sentiment around Boston Scientific's performance.
The details
Banque Pictet & Cie SA sold 41,572 shares of Boston Scientific during the fourth quarter, reducing its total position to 270,871 shares. The bank's holdings in Boston Scientific were valued at $25.83 million at the end of the reporting period.
- Banque Pictet & Cie SA filed the 13F report for the fourth quarter of 2025 on April 2, 2026.
The players
Banque Pictet & Cie SA
A Swiss private bank that manages investments and wealth for high-net-worth individuals and institutions.
Boston Scientific Corporation
A global medical device company that develops and markets a broad range of products used in less-invasive medical procedures.
The takeaway
This filing highlights the investment decisions of a major institutional investor in the medical device industry, providing insight into broader market trends and sentiment around Boston Scientific's performance.
